Among the clinical classifications of breast cancer [2], human epidermal growth factor receptor-2 (HER-2)-overexpressing breast cancer has a high risk of treatment failure because it spreads rapidly and is highly metastatic as well as drug resistant [3]. Here, ERBB2 is linked to breast carcinoma.